 (Arch Dis Child 1995; 73: 131-135) 
Although constitutional growth delay is considered to be a 'normal growth variant, it remains the most common reason for short stature in boys presenting to endocrine clinics. When such growth delay is accompanied by significant psychosocial impairment and/or educational difficulties, androgen or anabolic steroid treatment has been used to induce a rapid growth spurt. Methyltestosterone, oxandrolone, or fluoxymesterone for six months to several years have been used.' Retrospectively, all these agents improved growth velocity immediately but there was disagreement over whether final height was increased, decreased, or unchanged. More recent trials with low doses of the anabolic steroid oxandrolone2 or testosterone oenanthate3 for only three months suggested that both were effective in promoting short term growth without unduly accelerating bone growth or compromising predicted final height. In addition, oxandrolone seemed to be able to sustain growth acceleration during the three months after discontinuation of treatment. This, however, was only observed in early pubertal boys and not in prepubertal boys with testes volumes <4 ml. 4 This discrepancy may be explained by the fact that oxandrolone augments pituitary growth hormone secretion through a priming effect on the somatotrophs in the pubertal boy whereas in the prepubertal boy this is only observed with testosterone oenanthate treatment.5
The aim of the study was to assess whether very low doses of testosterone, as oral testosterone undecanoate 20 mg once daily, could accelerate growth velocity without an undue advance in bone age in boys suffering from constitutional delay of growth. The effects of such treatment on growth hormone and gonadotrophin secretion and testosterone concentration were also monitored.
Subjects and methods
Twenty three otherwise healthy prepubertal boys with height at or below the third centile for chronological age6 7 with chronological age between 11 0 and 14-0 years and bone age over 8-0 years were studied. Recruitment was from paediatric endocrinology clinics in Edinburgh (n= 17) and Cardiff (n=6). These clinics receive referrals from a wide area of the east of Scotland and Wales. After blocked randomisation, using two blocks of 12, each boy was randomly allocated to receive either two capsules of testosterone undecanoate (Organon Laboratories, Cambridge) 10 mg daily orally for six months or identical placebo capsules. All subjects were observed for a total of 18 months, including six months before and six months after treatment. Ethical permission for the study was granted by the paediatric/reproductive medicine ethics of medical research subcommittee of the Lothian Health Board and the child health ethics committee of the South Glamorgan Health Authority. Informed written consent was obtained from each boy's parent(s) after explanation of the procedures involved and provision of printed information. It was noted on the consent form that each child himself had freely consented to participate, and that he and his parent(s) were informed of their right to withdraw. The randomisation code for each patient was broken at the end of the 18 months study period so that further treatment, if any, could be considered.
At screening, a full history and examination for each subject was carried out to ensure that no treatable systemic illness, including endocrinopathy, was present. At onset and completion of treatment, full blood indices (Coulter S+IV analyser) and biochemical values (Monarch centrifugal, Beckman and Discrete analysers) were measured. At onset of treatment plasma testosterone concentration was measured immediately before and at half hourly intervals for eight hours after the first dose of testosterone undecanoate or placebo. A single morning testosterone concentration was measured after cessation of treatment and six months thereafter. Each subject underwent three sessions of nocturnal blood sampling during which blood samples were withdrawn at 20 minute intervals. Growth hormone, luteinising hormone, and follicle stimulating hormone (FSH) concentrations were then measured for the samples taken during an eight hour period starting one hour after the recorded time of sleep onset. The next morning a 0-25 ,ug/kg gonadotrophin releasing hormone (GnRH) stimulation test was carried out, and the greatest rise in luteinising hormone and FSH during the following hour recorded. These overnight sessions were carried out shortly before the start, shortly after, and six months after cessation of treatment.
Serum growth hormone was measured using an immunoradiometric assay, calibrated in terms of growth hormone international standard 80/505. The assay employed 125I-labelled mouse antigrowth hormone monoclonal antibody (from NETRIA, St Bartholemew's Hospital, London) and polyclonal antigrowth hormone antiserum (SAPU, Carluke) linked to insoluble magnetisable Dynospheres (Dyno Particles AS, Lillestrom, Norway). Internal quality control samples were included (between-batch coefficient of variation <8-5% from 2-2-49 mU/l of growth hormone), and performance in the UK national external quality assessment scheme for growth hormone was also satisfactory.
The gonadotrophin assays were performed using Delfia kits (Pharmacia Wallac, Turku, Finland). Fifty microlitres of samples were assayed in duplicate. The within-assay coefficients of variation based on 30 consecutive duplicates of quality controlled pooled plasma samples were 9-1%, 6-3%, and 7-1% for mean hormonal concentrations of 0-24, 0-48, and 0-96 U/1 respectively. The average betweenassay coefficients of variation were 7 5%. The mean detection limit of the assay was 0 04 U/1.
Statistical analysis using Student's t test was performed with Microsoft Statworks.
Results
No subject was withdrawn from the study due to non-compliance (evidenced on direct inquiry or by leftover capsule counts) or side effects. It did not prove possible to collect full data on heart rate, blood pressure, skinfold thickness, bone age, and blood sampling for six of the subjects. Measurements of growth on all 23 subjects were used to calculate velocities of their change during three six month periods: before treatment, during treatment, and after treatment. Growth velocities were A double blind, placebo controlled study of the effects of low dose testosterone undecanoate on the growth ofsmallfor age, prepubertal boys Time (hours) Figure 2 Mean (SEM) testosterone concentrations in treated group after ingestion offirst 20 mg dose of testosterone undecanoate (n= 9) and in placebo group (n8).
during treatment. The testosterone absorption studies of the treated group showed a peak concentration of 16sO (25) nmo/l, reached at 29 (06) hours after ingestion of the first capsules (fig 2) .
A summary of mean and maximum nocturnal growth hormone, luteinising hormone, and FSH concentrations, response to GnRH and early morning testosterone and dihydrotestosterone concentrations during the study are shown in table 3. There were no significant differences between the testosterone undecanoate treated and placebo groups at any stage of the study as regards physiological growth hormone, luteinising hormone, or FSH secretion overnight, GnRH stimulated gonadotrophin rises or early morning testosterone or dihydrotestosterone concentrations. Discussion Short stature can be emotionally disabling and restrain the full realisation of a child's physical and intellectual potential.14 15 The efficacy of anabolic or sex steroids in promoting short term growth and increasing final height is as yet unproved. Carefully designed, controlled, prospective trials to determine the optimum regimen for growth acceleration are of great potential therapeutic benefit to many children. 16 This study was designed to assess if low dose short term treatment with an orally active androgen can fulfil the therapeutic goal of promoting and sustaining skeletal growth while minimising epiphyseal maturation.
There are disadvantages associated with any relatively short term study of growth. In particular, with regard to studies around the time of puberty, it has been suggested that the evaluation of pubertal growth in pathological situations, and even physically physiological situations such as constitutional delay, should be performed using total pubertal height gain rather than peak height velocity or growth rate which are calculated after a follow up of shorter periods. In general, peak height velocity and/or growth rate are used because most studies are performed and completed before final height has been reached. We could not assess total pubertal height gain because each subject was recruited on the understanding that further or other growth promoting treatment could be instigated on completion of the 18 month assessment period. In addition, GnRH=gonadotrophin hormone releasing hormone.
the object of the study was to assess the growth promoting effects of low dose testosterone undecanoate during and for a six month period after treatment, as the effect in this subgroup of boys, who often present with psychosocial difficulties, would require a fairly rapid effect. wvhen the preparation is taken with food in the morning. '8-20 In studies of boys in early puberty the drug has been administered in higher dose in the evening.21
The accelerated gain in height (in particular sitting height) during the six months of treatment, without a significantly enhanced increase in bone age, is an encouraging finding which suggests that even at this low dose testosterone undecanoate taken orally can accelerate height gain and give a much needed psychological advantage to boys in this situation.
Further work is needed to determine the optimum length of treatment. Longer periods of observation would be required to assess the effect on final adult height. In this group of boys, however, final adult height is not the primary concern. As all cases of growth delay have significant bone age retardation, they will usually attain a reasonable adult height without intervention. More often it is the immediate future that concerns these subjects, so that a reasonably rapid acceleration of height gain in the short term can be seen as a positive outcome, provided that it is not accompanied by an excessive acceleration of skeletal maturity. Our results show that testosterone undecanoate is a safe, well tolerated, and effective treatment in the management of constitutional delay of growth.
